Celldex Therapeutics (CLDX) Receivables (2010 - 2026)

Celldex Therapeutics' Receivables history runs 17 years deep, the most recent figure standing at $230000.0 for Q1 2026.

• In Q1 2026, Receivables fell 78.38% year-over-year to $230000.0; the TTM figure through Mar 2026 stood at $230000.0 (down 78.38% YoY), while the FY2025 annual figure was $2.0 million, up 187.86% from the prior year.
• Receivables was $230000.0 for Q1 2026 at Celldex Therapeutics, down from $2.0 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $2.7 million in Q1 2024 to a low of $90000.0 in Q2 2025.
• Historically, Receivables has averaged $849058.8 across 5 years, with a median of $347000.0 in 2022.
• The sharpest annual moves came in 2024 and 2025: Receivables soared 1200.0% in 2024, then sank 94.13% in 2025.
• A 5-year view of Receivables shows it stood at $347000.0 in 2022, then surged by 657.35% to $2.6 million in 2023, then sank by 73.36% to $700000.0 in 2024, then soared by 187.86% to $2.0 million in 2025, then slumped by 88.59% to $230000.0 in 2026.
• The last three Receivables figures came in at $230000.0 (Q1 2026), $2.0 million (Q4 2025), and $90000.0 (Q3 2025), per Business Quant data.